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Fungus-ﬁghting vaccine
 
On page 597, Torosantucci and colleagues 
describe a novel vaccine with the potential 
to confer protection against multiple 
fungal pathogens. In mice, the vaccine 
induced protective immunity against 
 
Candida albicans
 
 and 
 
Aspergillus fumigatus
 
, 
both common fungal pathogens that prey 
on immunocompromised individuals.
Vaccination generates anti– -glucan anti-
bodies that inhibit Candida hyphae.
 
Recruiting interferon producers
 
On page 687, Diacovo and colleagues describe how natural
interferon-producing cells (IPCs) make their way from the
bloodstream into the peripheral lymph nodes (PLNs), where
they help fight pathogens.
IPCs, also called plasmacytoid dendritic cells (DCs), are
the major producers of type I interferons and respond to
virus infection using intracellular Toll-like receptors that
bind viral RNA or DNA. During infection, IPCs accumulate
in secondary lymphoid tissue where they boost the antiviral
function of other cells, including natural killer cells and
DCs, but how they gain entry into the lymph nodes had
been a mystery until now.
Using intravital microscopy, which enables real-time
viewing of cellular movement in vivo, Diacovo and colleagues
showed how inflammation drives IPC migration into PLNs.
The important players in this process were adhesion molecules
called selectins. L-selectin expressed on the surface of blood-
borne IPCs and E-selectin expressed on specialized endothelial
venules in the PLNs promoted IPC attachment to and rolling
along the vessel endothelium during inflammation. 
 
 
 
1
 
- and
 
 
 
2
 
-integrins expressed on the cell surface then allowed IPCs
to establish a firm foothold on the vessel wall. Finally, the
chemokine receptor CCR5 was shown to be necessary for
the IPCs to squeeze through the endothelial cells lining the
vessel wall into the PLNs.
 
Effective antifungal therapy can be 
hampered by drug toxicity and acquired 
resistance. A therapeutic or prophylactic 
vaccine might circumvent these problems, 
but none are commercially available.
 
 
 
-glucan, a polysaccharide component of all 
pathogenic fungal cell walls, is an attractive 
antigenic target for vaccine development 
as it is critical for survival and is not 
expected to readily mutate in response to 
immune pressure—a common problem for 
vaccination against highly mutable proteins 
such as the HIV envelope protein.
In their study, Torosantucci and 
colleagues used laminarin, a well-
characterized 
 
 
 
-glucan from the brown alga 
 
Laminaria digita
 
, as a source of immunizing 
antigen. Laminarin’s weak immunogenicity 
was overcome by hooking it up to the highly 
immunogenic diptheria toxin, a protein 
carrier commonly used in human vaccines.
Mice and rats immunized with this 
vaccine developed anti–
 
 
 
-glucan 
antibodies and were protected against 
otherwise lethal challenge with 
 
C. albicans
 
 
and 
 
A. fumigatus
 
. Immune serum and a 
 
 
 
-glucan specific monoclonal antibody 
also protected naive mice when transferred 
intravenously. In vitro, anti–
 
 
 
-glucan 
antibodies bound preferentially to 
 
C. 
albicans
 
 hyphae and inhibited fungal 
growth in the absence of cells, suggesting 
that protection was antibody mediated 
rather than cell mediated. Thus the vaccine 
might protect individuals with defects in 
the phagocytic cells that normally attack 
fungal invaders.
“This is the first time that a single 
vaccine formulation has been effective 
against such diverse pathogens as 
 
Candida
 
 
and 
 
Aspergillus
 
,” says senior author, 
Antonio Cassone. The authors now plan to 
test this vaccine in humans. They also plan 
to test it against certain bacteria and 
protozoa known to express glucan or 
glucan-like molecules. 
 
These findings distinguish IPC migration patterns from
those of conventional DCs, which migrate into the lymph
node from peripheral tissues through afferent lymphatics. The
authors suggest that IPCs might use the same receptors to gain
access to other inflamed tissues such as the skin. If so, inter-
fering with the function of these receptors might be therapeutic
in the treatment of autoimmune disorders, such as psoriasis
and systemic lupus erythematosus, in which IPCs accumulate
in the skin and contribute to disease pathogenesis. 
Immigrant IPCs (red) are found clustered near specialized venules 
(center) in inflamed lymph nodes.
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